Education
About Us
Working with TipRanks
Follow Us
Nectar Lifesciences Ltd. (IN:NECLIFE)
:NECLIFE
NECLIFE Stock Chart & Stats
₹18.25
-₹0.79(-2.00%)
At close: 4:00 PM EST
₹18.25
-₹0.79(-2.00%)
Day’s Range― - ―
52-Week Range₹12.51 - ₹30.65
Previous CloseN/A
Volume216.67K
Average Volume (3M)34.32K
Market Cap
₹2.94B
Enterprise Value₹7.36B
Total Cash (Recent Filing)₹197.51M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.64
Shares Outstanding224,260,970
10 Day Avg. Volume25,321
30 Day Avg. Volume34,323
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.56
Price to Sales (P/S)0.32
P/FCF Ratio4.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Revenue StreamsMultiple product segments and distribution channels (honey/bee products, pharma, nutraceuticals, exports, distributor partnerships) provide durable revenue diversification. This reduces dependence on a single market, supports cross-selling, and cushions the business versus localized demand shocks.
R&D And Quality FocusA sustained emphasis on R&D, quality and sustainability underpins product differentiation and regulatory compliance in health-focused markets. Over months this supports premium positioning, new product introductions, and stronger barriers to entry versus commodity competitors.
Improving Operating Cash FlowRecent improvement in operating cash flow, despite historical volatility, indicates the company can generate cash from operations intermittently. Persisting this trend would enhance liquidity, fund working capital and capex, and reduce reliance on external financing for sustained operations.
Bears Say
Significant Revenue DeclineA roughly 30% year-on-year revenue decline is a durable headwind: it erodes scale economics, strains fixed-cost absorption, reduces bargaining power with suppliers, and limits reinvestment capacity. Continued top-line contraction undermines long-term growth prospects and strategic initiatives.
Persistent Margin PressureReported negative net profit margin and declining gross margin signal structural cost or pricing issues. Sustained margin erosion reduces free cash flow and the ability to fund R&D or marketing, increasing the likelihood of cost restructuring and impairing long-term competitiveness.
Negative Return On EquityNegative recent ROE indicates the company is not generating acceptable returns on shareholder capital. Over months this undermines investor confidence, complicates capital raising or favorable financing, and may force dilution or strategic shifts to restore profitability and shareholder value.
Nectar Lifesciences Ltd. News
NECLIFE FAQ
What was Nectar Lifesciences Ltd.’s price range in the past 12 months?
Nectar Lifesciences Ltd. lowest stock price was ₹12.51 and its highest was ₹30.65 in the past 12 months.
What is Nectar Lifesciences Ltd.’s market cap?
Nectar Lifesciences Ltd.’s market cap is ₹2.94B.
When is Nectar Lifesciences Ltd.’s upcoming earnings report date?
Nectar Lifesciences Ltd.’s upcoming earnings report date is Jun 03, 2026 which is in 100 days.
How were Nectar Lifesciences Ltd.’s earnings last quarter?
Nectar Lifesciences Ltd. released its earnings results on Jan 23, 2026. The company reported ₹0.636 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.636.
Is Nectar Lifesciences Ltd. overvalued?
According to Wall Street analysts Nectar Lifesciences Ltd.’s price is currently Overvalued.
Does Nectar Lifesciences Ltd. pay dividends?
Nectar Lifesciences Ltd. pays a Annually dividend of ₹4.319 which represents an annual dividend yield of N/A. See more information on Nectar Lifesciences Ltd. dividends here
What is Nectar Lifesciences Ltd.’s EPS estimate?
Nectar Lifesciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nectar Lifesciences Ltd. have?
Nectar Lifesciences Ltd. has 224,260,970 shares outstanding.
What happened to Nectar Lifesciences Ltd.’s price movement after its last earnings report?
Nectar Lifesciences Ltd. reported an EPS of ₹0.636 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.549%.
Which hedge fund is a major shareholder of Nectar Lifesciences Ltd.?
Currently, no hedge funds are holding shares in IN:NECLIFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nectar Lifesciences Ltd.
Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company offers contract research and manufacturing services, including process development and optimization, process scale up and validation, preparation and international submission of drug master files and certificates of suitability, multi kilo pilot plant production, bulk production, and chiral resolution; and chemical and analytical development, as well as analytical, manufacturing, and engineering consulting services. Its active pharmaceutical ingredients and intermediates comprise cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCl, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. The company also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, it provides a range of diagnostics products; empty hard gelatin capsules; and menthol products. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.
Technical Analysis
Ind-Swift Laboratories Ltd.
―
Medicamen Biotech Limited
―
Sakar Healthcare Ltd
―
Venus Remedies Limited
―
Zim Laboratories Ltd.
―